XML 28 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 17, 2026
Jun. 30, 2024
Cover [Abstract]      
Registrant Name MEDICUS PHARMA LTD.    
Registrant CIK 0001997296    
Current Fiscal Year End Date --12-31    
Document Type 10-K    
Document Annual Report true    
Entity File Number 001-42408    
Document Financial Statement Error Correction [Flag] false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Incorporation, State or Country Code A6    
Entity Tax Identification Number 98-1778211    
Entity Address, Address Line One 300 Conshohocken State Rd.    
Entity Address, City or Town W. Conshohocken    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19428    
City Area Code 610    
Local Phone Number 636-0184    
Title of 12(g) Security Common shares, no par value    
Trading Symbol MDCX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Shell Company false    
Entity Public Float     $ 28.3
Entity Common Stock, Shares Outstanding   39,362,109  
Amendment Flag false    
Document Transition Report false    
Entity Ex Transition Period false    
Auditor Firm ID 185    
Auditor Name KPMG LLP    
Auditor Location New York, New York    
Documents Incorporated by Reference

The information required by Part III of this Annual Report, to the extent not set forth herein, is incorporated herein by reference from the registrant's definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2025, which definitive proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates, unless such definitive proxy statement is not filed prior to 120 days after the end of the fiscal year to which this Annual Report relates, in which case the information relating to this item will be filed by amendment to this Annual Report.

    
Auditor Opinion

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of Medicus Pharma Ltd. and subsidiaries (the Company) as of December 31, 2025, the related consolidated statements of operations and comprehensive loss, changes in shareholders' equity, and cash flows for the year then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles.

    
Rule 10b5-1 Arrangement Terminated [Flag] true